Jefferies Remains Bullish on Compugen (CGEN) - PT to $9
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results
February 9, 2016 7:09 AM EST
HOLON, Israel, Feb. 9, 2016 /PRNewswire/ --Â Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported financial results for the fourth quarter and year ended December 31, 2015.
Anat Cohen-Dayag, Ph.D., Compugen's President and Chief Executive Officer, stated, "This past year was a year of significant accomplishment for our company with respect to our unique discovery infrastructure and our target pipeline program. Important to both was the demonstration of functional activity in preclinical models of cancer immunotherapy for an immune checkpoint antibody program for which the target... More
